Clinical Trial Update: Comparative Study of Oestradiol Suppression: Zoladex 10.8mg/3 Month vs. 3.6mg/Month in ER +ve EBC Pre-menopausal Patients [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing two dosing regimens of Zoladex (goserelin) for estrogen suppression in premenopausal ER-positive breast cancer patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Zoladex (goserelin)

Snippet

Sponsor: AstraZeneca | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED